Analyst group logo

Latest news

Comment

2024-12-20

Comment on STENOCARE’s Announcement of a Conditional Rights Issue of up to DKK 20.2m
Read more

Comment

2024-12-19

Kommentar på AcuCorts inlämnade iPSP-ansökan till FDA
Read more

Comment

2024-12-18

Kommentar på Obducats senaste ordrar
Read more

Comment

2024-12-17

Kommentar på Titanias förvärv av Byggmästaren 2 i Solna
Read more

Comment

2024-12-17

Comment on STENOCARE’s Approval for a new Medical Cannabis CBD100 oil
Read more

Comment

2024-12-13

Comment on Pharma Equity Group’s New Execution Strategy
Read more

Analysis

2024-12-11

Tangiamo Touch Q3-24
Read more

Text interview

2024-12-11

Interview with MPC Container Ships’ Co-CEO and CFO Moritz Fuhrmann
Read more

Text interview

2024-12-10

Interview with Icelandic Salmon’s CEO Björn Hembre
Read more

Comment

2024-12-09

Kommentar på Tangiamos utvecklingsavtal med Tech (Macau) Ltd
Read more

Analysis

2024-12-06

Zoomability Q3-24
Read more

Analysis

2024-12-06

Analysartikel – Phase Holographic Imaging
Read more

Rights Issue

2024-12-06

Emission: Phase Holographic Imaging
Read more

Analysis

2024-12-05

CirChem Q3-24
Read more

Analysis

2024-12-05

AcuCort Q3-24
Read more

Comment

2024-12-04

Comment on ODI Pharma’s Update on Poland’s Expanding Medical Cannabis Market
Read more

Text interview

2024-12-04

Interview with Glaston’s CEO Toni Laaksonen
Read more

Analysis

2024-12-04

MoveByBike
Read more

Text interview

2024-12-03

Interview with Aspo’s CEO Rolf Jansson
Read more

Comment

2024-12-02

Kommentar på AcuCorts Q3-rapport samt företrädesemission
Read more

Analysis

2024-12-02

ODI Pharma Q1-24/25
Read more

Comment

2024-12-02

Comment on that STENOCARE’s Astrum Oil has been Approved for Sales in Norway
Read more

Analysis

2024-12-02

Ramlösa Shipping Q3-24
Read more

Analysis

2024-12-02

Kinda Brave Q3-24
Read more

Comment

2024-11-29

Comment on the Outcome of Irisity’s Rights Issue
Read more

Comment

2024-11-29

Kommentar på Tangiamos Q3-rapport
Read more

Comment

2024-11-28

Kommentar på Zoomabilitys Q3-rapport
Read more

Analysis

2024-11-28

Embark Group Q3-24
Read more

Comment

2024-11-28

Analyst Group inleder analysbevakning av Neovici
Read more

Comment

2024-11-27

Kommentar på Zoomabilitys senaste nyheter om Zoom Stick
Read more

Comment

2024-11-27

Kommentar på MoveByBikes Q3-rapport
Read more

Video

2024-11-27

Intervju med Luxbrights VD Mats Alm
Read more

Text interview

2024-11-27

Interview with Betolar’s CEO Tuija Kalpala
Read more

Comment

2024-11-27

Comment on STENOCARE Shifting Strategy to Focus on Trading and Exit from Production
Read more

Analysis

2024-11-27

First Venture Q3-24
Read more

Comment

2024-11-26

Kommentar på Ramlösa Shippings Q3-rapport
Read more

Comment

2024-11-26

Kommentar på AcuCorts medverkan på den vetenskapliga konferensen ISPOR i Barcelona
Read more

Text interview

2024-11-26

Intervju med Job Solutions VD Viktor Rönn
Read more

Comment

2024-11-25

Kommentar på Kinda Braves Q3-rapport
Read more

Comment

2024-11-25

Comment on ODI Pharma’s Quarterly Report
Read more

Text interview

2024-11-25

Interview with Tulikivi’s CEO Heikki Vauhkonen
Read more

Analysis

2024-11-25

Titania
Read more

Comment

2024-11-25

Kommentar på Embark Groups Q3-rapport
Read more

Video

2024-11-25

Intervju med Titanias VD Einar Janson
Read more

Analysis

2024-11-22

EcoRub Q3-24
Read more

Text interview

2024-11-22

Interview with LeadDesk’s CEO Olli Nokso-Koivisto
Read more

Analysis

2024-11-21

Umida Group Q3-24
Read more

Comment

2024-11-21

Kommentar på First Ventures Q3-rapport
Read more

Comment

2024-11-21

Kommentar på Kinda Braves förlagsavtal med Aurora Punks avseende spelet Go Fight Fantastic
Read more

Analysis

2024-11-20

Björn Borg Q3-24
Read more

Comment

2024-11-20

Kommentar på Luxbrights verksamhetsuppdatering
Read more

Analysis

2024-11-20

Obducat Q3-24
Read more

Comment

2024-11-20

Comment on the Danish Health Minister’s Decision to Propose a Permanent Legalization of Medical Cannabis
Read more

Analysis

2024-11-19

Pharma Equity Group Q3-24
Read more

Analysis

2024-11-19

Refine Group Q3-24
Read more

Text interview

2024-11-18

Interview with Kongsberg Gruppen’s Jan Erik Hoff
Read more

Analysis

2024-11-15

Irisity
Read more

Comment

2024-11-15

Comment on PEG’s Q3 Report for 2024
Read more

Comment

2024-11-15

Comment on Björn Borgs Q3 Report for 2024
Read more

Comment

2024-11-14

Kommentar på CirChems Q3-rapport
Read more

Text interview

2024-11-14

Interview with Multiconsult’s CFO Ove B. Haupberg
Read more

Comment

2024-11-14

Kommentar på Umidas Q3-rapport 2024
Read more

Text interview

2024-11-14

Interview with Lamor’s CEO Johan Grön
Read more

Analysis

2024-11-14

Zoomability – Analysartikel
Read more

Video

2024-11-13

Interview with Irisity’s CEO Keven Marier
Read more

Video

2024-11-13

Intervju med Zoomabilitys VD Pehr-Johan Fager
Read more

Rights Issue

2024-11-13

Emission: Zoomability
Read more

Comment

2024-11-13

Kommentar på att samtliga patienter har genomgått AcuCorts Fas 4-studie (ZEQ001)
Read more

Rights Issue

2024-11-13

Emission: Irisity
Read more

Analysis

2024-11-13

Irisity
Read more

Text interview

2024-11-12

Interview with poLight’s CEO Øyvind Isaksen
Read more

Analysis

2024-11-11

STENOCARE Q3-24
Read more

Comment

2024-11-11

Kommentar på Obducats Q3-rapport
Read more

Comment

2024-11-08

Kommentar på Refine Groups Q3-rapport 2024
Read more

Comment

2024-11-07

Kommentar på Ramlösa Shippings investering i containerfartyget PASCARA
Read more

Text interview

2024-11-07

Interview with Soiltech’s CFO Tove Vestlie
Read more

Comment

2024-11-06

Comment on STENOCARE’s Q3-Report 2024
Read more

Comment

2024-11-05

Kommentar på MoveByBikes utökade samarbete med Airmee
Read more

Comment

2024-11-05

Comment on Irisity’s Q3-report
Read more

Text interview

2024-11-05

Interview with Kreate Group’s CEO Timo Vikström
Read more

Newsletter

Subscribe to be the first to get our news and latest reports